Asset profile
PF-06865571 Monotherapy
Unknown / undisclosed
Evidence outlook · program status
Divested (2025-12), as a strategic decision by the sponsor
PF-06865571 is ervogastat, Pfizer's oral DGAT-2 inhibitor for MASH. Pfizer did not take it further itself but out-licensed it globally to Madrigal Pharmaceuticals in December 2025; Madrigal's FY2025 10-K describes the licence and plans a drug-drug interaction study with resmetirom and FDA consultation on a Phase 2 combination trial in 2026, so the asset is alive under a new owner. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
30 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 29 same-indication; 13 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PF-06865571 Monotherapy: this drug | Phase 2 | — | Diacylglycerol acyltransferase 2 (DGAT2) | ||
| PF-06865571 | Phase 2 | — | Diacylglycerol acyltransferase 2 (DGAT2) | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Belapectin | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| GR-MD-02 | Phase 2/3 | Protein / enzyme therapeutic | Galectin-3 | ||
| ALN-HSD | Phase 2 | RNA / oligonucleotide | HSD17B13 |
…and 15 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.